Literature DB >> 3554999

Pregnancy: an overfill or underfill state.

R W Schrier, J A Dürr.   

Abstract

With pregnancy, the expansion of plasma and extracellular fluid volume, increased cardiac output, and increased glomerular filtration rate (GFR) and renal blood flow (RBF) are compatible with primary renal sodium and water retention with secondary enlargement of the vascular compartment (overfill hypothesis). Alternatively, a primary enlargement of the vascular compartment (eg, prostaglandin-mediated vasodilation and placental arteriovenous shunting) with secondary renal sodium and water retention (underfill hypothesis) is supported by the activation of the renin-angiotensin-aldosterone (RAA) system, resetting of vasopressin release and thirst to a lower plasma osmolality, and a further stimulation of the RAA system and vasopressin when pregnant rats' water intake is maintained at a level of a virgin rat fluid intake, diminished BP and increased cardiac output in the first trimester, and worsening of hyponatremia with sodium restriction in the pregnant but not the virgin rat. With the underfill hypothesis, normal sodium and water excretion with mineralocorticoid escape could be mediated by hormonally induced increases in GFR and RBF associated with pregnancy. The nature of such a hormone effect of pregnancy to enhance renal hemodynamics remains to be defined.

Entities:  

Mesh:

Year:  1987        PMID: 3554999     DOI: 10.1016/s0272-6386(87)80123-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  The effects of food restriction on maternal endocrine adaptations in pregnant rats.

Authors:  J P Leizea; C G González; F D García; A M Patterson; S F Fernández
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

Review 2.  Water retention and aquaporins in heart failure, liver disease and pregnancy.

Authors:  R W Schrier; M A Cadnapaphornchai; M Ohara
Journal:  J R Soc Med       Date:  2001-06       Impact factor: 5.344

3.  Differential effects of mineralocorticoid blockade on the hypothalamo-pituitary-adrenal axis in pregnant and nonpregnant ewes.

Authors:  Melissa Lingis; Elaine M Richards; Maureen Keller-Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-04       Impact factor: 4.310

Review 4.  The enigma of continual plasma volume expansion in pregnancy: critical role of the renin-angiotensin-aldosterone system.

Authors:  Crystal A West; Jennifer M Sasser; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-05

5.  Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation.

Authors:  J M Davison; E A Shiells; P R Philips; M D Lindheimer
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

Review 6.  Novel drug mechanisms in development for heart failure.

Authors:  Soidjon D Khodjaev; John R Teerlink; Fady I Malik
Journal:  Pflugers Arch       Date:  2014-05-06       Impact factor: 3.657

Review 7.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

8.  Regulation of maternal ACTH in ovine pregnancy: does progesterone play a role?

Authors:  Maureen Keller-Wood; Charles E Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-08-12       Impact factor: 4.310

Review 9.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

10.  Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats.

Authors:  Vanessa M Ferreira; Thiago S Gomes; Luciana A Reis; Alice T Ferreira; Clara V Razvickas; Nestor Schor; Mirian A Boim
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.